Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus AI (NASDAQ:TEM) announced a major expansion of its AI-enabled Next platform to deliver real-time clinical intelligence and close care gaps in oncology.
The platform now supports six new clinical scenarios and is backed by a multi-center eNSCLC study showing higher biomarker testing and guideline-concordant therapy.
Tempus AI (NASDAQ: TEM) announced a major upgrade to its smart physician platform Tempus Hub on May 27, 2026. The platform now embeds a next-generation, agentic generative AI co-pilot directly into Hub to support oncology clinical workflows at the point of care.
Key features include proactive AI genomic patient insights, instant generation of patient-specific documentation using Tempus data, and future plans to connect genomics results with Tempus’ longitudinal patient registry and HIE data. The upgrade builds on Tempus’ Edge, Locker, and Air infrastructure to link AI with real-time healthcare data.
Tempus AI (NASDAQ:TEM) announced that 37 abstracts have been accepted for presentation at the 2026 ASCO Annual Meeting, held May 29–June 3 in Chicago.
Accepted research spans AI-augmented histopathology, RNA-based algorithms, real-world treatment outcomes, AI-enabled biomarker testing tools, whole genome sequencing, and minimal residual disease monitoring across multiple solid and hematologic cancers.
Tempus AI (NASDAQ:TEM) announced the clinical launch of the ArteraAI Prostate Test (mHSPC), a CLIA-certified, CAP-accredited prognostic digital pathology test for metastatic hormone-sensitive prostate cancer. Fully integrated into the Tempus platform, it combines biopsy image analysis with clinical data and Tempus’ NGS results to personalize therapy intensity.
The test is the first externally developed digital pathology algorithm available for clinical use within the Tempus ecosystem and targets an estimated 25,000 newly diagnosed metastatic prostate cancer patients annually in the U.S. Clinicians can order it as an add-on across Tempus’ solid tumor portfolio.
Bristol Myers Squibb (NYSE: BMY) and Tempus AI announced an expanded collaboration using AI, multimodal real-world data, and the Tempus Lens platform to optimize clinical trial design and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial development programs.
The initiative supports solid tumor oncology assets in lung, colon, and prostate cancers and extends into neuroscience for Alzheimer’s disease. It focuses on refining trial assumptions, characterizing complex patient populations, validating control groups, and identifying optimal patient segments for investigational therapies.
Ambry Genetics, a subsidiary of Tempus AI (NASDAQ:TEM), announced that its CARE Program won the 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution.”
The EHR-integrated CARE platform supports breast and hereditary cancer risk assessment, embeds genetic tools into clinical workflows, and connects patients with genetic counselors for more proactive, standardized care.
Tempus (NASDAQ: TEM) priced an upsized private placement of $400.0 million 0.00% convertible senior notes due 2032, with an initial purchaser option for an additional $60.0 million. Net proceeds are estimated at $384.1 million (or ~$441.9 million if option exercised).
Proceeds are earmarked to repay $307.7 million of senior secured debt, pay ~$27.2 million for capped-call transactions, and for general corporate purposes. Initial conversion rate is 14.4388 shares per $1,000 principal (≈$69.26 per share); capped-call cap price is $98.94.
Tempus (NASDAQ:TEM)/b) announced a proposed private offering of
Lucent Diagnostics and Tempus AI (NASDAQ: TEM) announced a collaboration to integrate the LucentAD® Complete blood-based Alzheimer’s biomarker panel into Tempus Next care gap workflows and the Tempus clinical ordering platform.
The agreement makes LucentAD Complete available for neurologists to order via existing EHR integrations, aims to embed guideline-directed patient identification, and seeks to increase evaluation of patients eligible for approved Alzheimer’s treatments.
Tempus (NASDAQ: TEM) reported Q1 2026 revenue of $348.1M, up 36.1% year‑over‑year, with Diagnostics revenue of $261.1M (+34.7%) and Data & Applications revenue of $87.0M (+40.5%). Gross profit was $222.0M. Cash and marketable securities totaled $643.8M as of March 31, 2026. Net loss was $(125.9M); Adjusted EBITDA was $(2.8M). Tempus raised 2026 revenue guidance to $1.59–$1.60B and expects ~$65M Adjusted EBITDA for the year.